Fennec Pharmaceuticals Q2 EPS $(0.21) Misses $(0.16) Estimate, Sales $3.33M Miss $3.73M Estimate
Portfolio Pulse from sunil@benzinga.com
Fennec Pharmaceuticals reported Q2 losses of $0.21 per share, missing the analyst consensus estimate of $0.16 by 31.25%. This is a 10.53% decrease from the same period last year. The company also reported quarterly sales of $3.33 million, missing the analyst consensus estimate of $3.73 million by 10.86%.
August 04, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fennec Pharmaceuticals reported lower than expected Q2 earnings and sales, which could negatively impact its stock price in the short term.
Fennec Pharmaceuticals reported a larger than expected loss and lower than expected sales for Q2. This negative earnings surprise could lead to a decrease in the company's stock price as it indicates that the company is not performing as well as investors expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100